Shenzhen Chipscreen Biosciences Co., Ltd., established in March 2001 by a group of senior scientists returned from the United States, is a pioneer in drug innovation and development in China. With a comprehensive vision in emphasizing innovation, safety and quality, Chipscreen Biosciences focuses on developing innovative drugs with new mechanisms of action (MOA) for the treatment of human diseases in five major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders and antivirals, so as to provide patients with affordable, efficacious drugs to meet their clinical needs. Chipscreen Biosciences was the first biotech company approved for listing on the SSE STAR Market (stock code: 688321.SH).
Over the past 21 years, Chipscreen Biosciences has perfected a core technology platform for innovative drug discovery (a.k.a. integrated drug discovery and early evaluation platform based on chemical genomics) that has greatly improved the efficiency of clinical drug development, shortening the development time and reducing failure rates. On the back of this core technology, Chipscreen Biosciences has successfully developed a series of national class I drugs featuring new molecular entities and MOA, including the anti-tumor epigenetic regulator Chidamide, the new-generation insulin sensitizer Chiglitazar for the treatment of type 2 diabetes, the triple-pathway targeted kinase inhibitor Chiauranib, and the autoimmune disorder inhibitor CS12192. An additional 20 projects covering multiple therapeutic areas are at varying stages in the development pipeline, from early drug discovery to preclinical research. Notably, Chidamide, as the first product of Chipscreen approved by China in 2014, is the first original innovative drug in the history of the Chinese pharmaceutical industry, and also China’s first new drug patented in developed countries for global development.
At present, Chipscreen Biosciences has formed a global industrial layout consisting of Shenzhen Headquarters/R&D Center, GMP manufacture (Shenzhen Chipscreen Pharmaceutical Ltd., a wholly-owned subsidiary), Regional Headquarters/R&D Center/innovative drug manufacture in Chengdu (Chengdu Chipscreen Pharmaceutical Ltd., a wholly-owned subsidiary), Chengdu Chipscreen Newway Biosciences Co., Ltd. (committed to the development of large molecules and other novel therapeutic technologies other than small molecules), Beijing Branch (Clinical Research Center), Shanghai Branch (Business Center), and Chipscreen Biosciences (US) Co., Ltd.
Moreover, as a "National Innovative Drug Incubation Base" and a "National High-Tech Enterprise", CHIPSCREEN BIOSCIENCES has independently undertaken a multitude of national high-tech R&D programs (“863 Program”), national major science and technology projects incorporated into "the 10th five-year plan", the "11th five-year plan", the "12th five-year plan" and the "13th five-year plan", and the National Scientific and Technological Major Project for “Innovative Drug Development”. More than 500 invention patents have been applied at home and abroad, of which over 140 have been authorized.
Shenzhen Chipscreen Pharmaceutical Ltd.
Shenzhen Chipscreen Pharmaceutical Ltd., incorporated on Mar. 16, 2017, is located at No. 21, Jinxiu East Road, Kengzi Street, Pingshan New District, Shenzhen. A wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd., it was formerly the Pingshan manufacturing base of Chipscreen Biosciences, and is now the industrialization base for the Company’s first original anti-tumor drug, Chidamide. The subsidiary consists of the Group’s innovative drug CMC technology transfer center, an oncologic API and formulation workshop, a quality management center, and other production-related supporting facilities.
Chengdu Chipscreen Pharmaceutical Ltd.
Chengdu Chipscreen Pharmaceutical Ltd., incorporated on Apr. 28, 2014, is a wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. Consisting of two sites, the Innovative Drug Manufacturing Base and the Innovative Drug R&D Center and Regional Headquarters, Chengdu Chipscreen Pharmaceutical plays a pivotal role in the regional development of the Group.
The Innovative Drug Manufacturing：Base is located at No. 298, Kangqiang Yi Road, West High-tech Zone, Chengdu. The facilities here include oncology and non-oncology API and oral solid formulation workshops, which are designed in accordance with GMP standards of the US, EU and China. In order to fully meet demand for pilot scale testing of innovative drugs, preparation of clinical samples and production of commercial batches, new facilities including workshops for oncologic and non-oncologic injections and antibody drugs are under construction.
The Innovative Drug R&D Center and Regional Headquarters：is located at No. 18, Xintongnan Yi Road, Xinchuan Science and Technology Park, South High-tech Zone, Chengdu. A vital part of the Group’s R&D system, the Innovative Drug R&D Center will work with and complement the Early Research & Development Center (Shenzhen) in building product pipelines and supporting clinical research needed for the company’s sustainable development.
Beijing Branch of Shenzhen Chipscreen Biosciences Co., Ltd.,( Clinical Research Center of Shenzhen Chipscreen Biosciences Co., Ltd.,)
located in Chaoyang District, Beijing, is a Clinical Research and Operations Center, functioning as clinical project managements and supporting for drug registrations.
Shanghai Branch of Shenzhen Chipscreen Biosciences Co., Ltd., (Business Center of Shenzhen Chipscreen Biosciences Co., Ltd., )
located in Putuo District, Shanghai, is the Group’s marketing center, as well as the base for product strategy development and business expansion.
Chipscreen Biosciences (United States) Limited
Chipscreen Biosciences (United States) Limited was incorporated on Oct. 16, 2020. Registered in Newark, Delaware with its offices located in Somerset, New Jersey, Chipscreen Biosciences (United States) Limited is a wholly-owned subsidiary of Shenzhen Chipscreen Biotechnology Co., Ltd. that serves as the international clinical development center of the Company, assisting with Chipscreen’s globalization.
Chengdu Chipscreen Newway Biosciences Co., Ltd.
Chengdu Chipscreen Newway Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Newway") is an innovative biotechnology enterprise committed to the development of large molecules and other novel therapeutic technologies under Chipscreen Biosciences. Chipscreen Newway specializes in novel therapeutic methods and technologies including but not limited to nucleic acid drugs and large molecules represented by antibodies and Antibody–Drug Conjugates (ADC). We are dedicated to developing drugs with novel mechanisms of action that meet clinical needs in disease areas, such as tumors and autoimmune diseases, to provide patients with innovative and leading therapeutic methods and options.